Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
10 Moving Design Frill for Summer 2023 - 2The Conclusive Manual for Spending plan Travel: Opening Undertakings on a Tight budget
- 3Wizz CEO: We’re going to invest $1 b. in Israeli market
- 4Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- 5High-Suggested Broilers For Your Homes
- EU delegation urges China to tighten export controls
- Opening Innovativeness: Moving Thoughts and Tasks
- Audits of the Top Science fiction Movies This Year
- See the famous winged horse Pegasus fly in the autumn night sky
- Instructions to Comprehend and Use Open Record Extra Offers
- Manual for Conservative SUVs For Seniors
- NASA Artemis 2 astronauts to make historic moon flyby today. Here's what to expect hour by hour (timeline)
- Video Conferencing Instruments for Virtual Gatherings
- Advocacy groups react after Mattel introduces 1st Barbie doll with autism
